Company intelligence / Profile preview

ProstagoRx

Ownership: Private
Development stage: Other

Overview

ProstagoRx is an early-stage biotechnology company focused on developing novel therapeutic solutions for prostate cancer. The company's primary research efforts center on the development of next-generation androgen receptor modulators designed to overcome resistance mechanisms in castration-resistant prostate cancer. By targeting specific binding domains and co-regulator interactions, ProstagoRx aims to provide more effective treatment options for patients who have failed standard-of-care hormonal therapies. The company is currently advancing its lead candidates through pre-clinical validation and optimization.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on ProstagoRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProstagoRx.

Explore the full profile